ArticleFrontiers in psychiatry2026
A discovery plasma proteome signature in military personnel with chronic PTSD symptoms.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Post-traumatic stress disorder (PTSD) is highly prevalent among U.S. service members and veterans (SMV) and has lasting impacts on health and well-being. However, the biological underpinnings of PTSD remain poorly characterized. This study aimed to discover novel candidate proteins and protein pathways associated with PTSD using unbiased, high-throughput proteomics profiling. Methods: A cross-sectional study was conducted using a subset of SMV participants from a clinical cohort undergoing evaluations at the National Intrepid Center of Excellence, Walter Reed National Military Medical Center, who consented to a research blood draw and use of their clinical data in research. The cohort with available blood samples was classified into PTSD-Present and PTSD-Absent groups based on the PTSD Checklist-Civilian Version. Olink high-throughput proteomic profiling examined 5400 human plasma proteins, and differentially expressed proteins were examined. Ingenuity pathway analysis was used to identify proteomic pathways among the significant differentially expressed proteins between the PTSD-Present and PTSD-Absent groups. Results: We included 208 samples in our analysis, 126 with and 82 without PTSD. We identified 366 proteins that were significantly differentially expressed between groups, with the 3 most significant being LMOD2 (Leiomodin-2), ATP5F1D (ATP synthase δ-subunit), and CASKIN1 (CASK-interacting protein). Extracellular matrix organization pathways and Vascular Endothelial Growth Factor (VEGF) signaling were downregulated in PTSD, suggesting possible vascular inflammation and remodeling. Data-driven protein networks suggest reduced immune cell activation. Discussion: Determining differential protein expression and identifying the associated protein pathways linked to PTSD may provide new insights into the biological basis of chronic PTSD symptoms and help identify novel candidate protein biomarkers of PTSD and PTSD symptoms for validation in separate and larger cohorts. From this discovery cohort, we report that elevated PTSD symptoms may be associated with downregulation of extracellular matrix organization, inflammation signaling, and vascular remodeling pathways. Future research is necessary to validate this novel group of biomarkers and pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.